Mistakenly removing healthy kidney may cost hospital Medicare funding

Saint Vincent Hospital in Worcester, Massachusetts, may lose its Medicare funding because of safety and patient identification issues, including a very damaging mistake made by one surgeon.

According to the Boston Globe, prior to an operation, the surgeon checked a CT scan of the patient that showed a large tumor on the left kidney. However, that scan was for another patient with the same name, a fact which went unnoticed because the surgeon failed to use a second piece of identifying information, such as a birth date. The patient’s actual health record was missing a CT scan.

The mistake was discovered only after the perfectly healthy kidney had been removed and samples had been sent to the pathology lab.

While the hospital said its staff followed proper protocols, Massachusetts Department of Public Health inspectors found several patient ID problems at St. Vincent, including 30 surgical staffers who hadn’t been trained in identifying patients. The inspectors also said the hospital didn’t plan to thoroughly investigate the mix-up.

For more on the hospital’s issues and why CMS feels it has failed to make improvements quickly enough, click on the link below: 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.